Corporate Banner
Satellite Banner
RNAi
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Agilent Introduces HaloPlex Next-Generation Sequencing Panels

Published: Monday, June 17, 2013
Last Updated: Monday, June 17, 2013
Bookmark and Share
Catalog and custom panels enable rapid, targeted genomics analysis.

Agilent Technologies Inc. has introduced a new series of HaloPlex next-generation sequencing panels targeting specific disease states.

Two catalog products, the HaloPlex Cancer Research Panel and the HaloPlex Cardiomyopathy Research Panel, plus five predesigned research panels for arrhythmia, ICCG genomic regions, X chromosome, Noonan syndrome, and connective tissue disorders are now available.

Used in combination with Agilent’s SureDesign and SureCall software, the new panels enable laboratories to perform integrated data analysis, mapping and reporting with greater confidence, speed and flexibility.

“With the adoption of desktop sequencing, clinical research laboratories are increasingly interested in panels with predesigned content for routine analysis,” said Dr. Berivan Baskin, FACMG, FCCMG, clinical molecular geneticist at Uppsala University Hospital, who worked with Agilent to develop the panels.

Dr. Baskin continued, “These new HaloPlex panels, combined with Agilent’s analysis software, provide comprehensive content with high levels of sensitivity and specificity.”

“Clinical research laboratories commonly lack the time and resources necessary to individually define disease-related genes and incorporate them into their own custom sequencing panels,” said Jacob Thaysen, vice president and general manager of Agilent’s Genomics Solutions Division.

Thaysen continued, “So we have been working closely with industry experts to develop these targeted disease panels to help these laboratories dramatically improve their workflows and research outcomes.”

HaloPlex target-enrichment solutions combine the speed and specificity of polymerase chain reaction-based systems with the scalability and capture-size flexibility of solution-based hybridization formats, eliminating the need for library preparation.

This streamlined sequence-selective solution for next-generation sequencing helps to remove bottlenecks associated with targeted resequencing and eliminate the need for expensive, dedicated instrumentation or laborious protocols.

SureDesign and SureCall software programs are an integral part of Agilent’s complete solutions for next-generation sequencing target enrichment.

SureDesign increases flexibility by allowing HaloPlex panel users to develop custom panels and incorporate additional predesigned genes/regions of interest to suit their laboratory’s individual needs.

SureCall significantly reduces the data analysis hurdles faced by researchers, enabling simple and intuitive variant calling.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,900+ scientific posters on ePosters
  • More than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Influential Cancer Researcher Receives Agilent Thought Leader Award
Biologist Scott Lowe receives award in recognition for his contributions to cancer biology.
Thursday, October 27, 2016
Agilent’s Non-Small Cell Lung Cancer Companion Dx Receives Expanded FDA Approval
Agilent’s Dako PD-L1 IHC 22C3 pharmDx has an expanded label approved by the U.S. FDA for use in determining PD-L1 expression status to inform treatment in metastatic non-small cell lung cancer with KEYTRUDA® (pembrolizumab).
Tuesday, October 25, 2016
Agilent Technologies to Build New Facility in Colorado
Agilent buys 20 acres in Weld County to increase pharmaceutical manufacturing capacity.
Wednesday, August 10, 2016
Best Practices for Breast Cancer Diagnosis
Agilent has published “Breast Cancer Diagnosis: Past, Present and Future,” a white paper on the use of immunohistochemistry in diagnosing and treating breast cancer.
Monday, March 14, 2016
Dako, Cell Signalling Tech Partner with Companion Diagnostics
Partnership for development of high-quality, cutting-edge companion diagnostic products for diagnosis and treatment of cancer.
Monday, January 12, 2015
Agilent, Cell Line Genetics Collaborate
Companies to collaborate on high-throughput cell-line characterization services for regenerative medicine, cancer researchers.
Thursday, February 13, 2014
Dr. Emmanuel Barillot Receives Agilent Thought Leader Award
Award will support Dr. Barillot’s Web-based tools for cancer and drug-safety research.
Friday, August 30, 2013
Dako to Offer New Antibody in U.S. to Diagnose Breast Cancer
Dako receives clearance to sell FLEX Monoclonal Rabbit Anti-Human Estrogen Receptor a, Clone EP1 in US.
Monday, April 08, 2013
Agilent Technologies Thought Leader Award Supports Translational Research Program
The award will support Dr DePinho's research into metabolic reprogramming in the earliest stages of cancer.
Monday, March 04, 2013
Agilent Technologies Teams with University of Liverpool's Centre for Genomic Research
Centre for Genomic Research has become the UK's first Certified Service Provider for the Agilent SureSelect Target Enrichment System for next-generation sequencing.
Wednesday, August 08, 2012
Agilent Technologies Collaborates with Gachon University
World-leading research laboratory at Gachon will have access to the latest technologies from Agilent and a beta test site for new solutions.
Monday, July 23, 2012
Agilent Completes Acquisition of Dako, Danish Cancer Diagnostics Company
Acquisition to help strengthen Agilent's position in life sciences.
Thursday, June 28, 2012
Agilent to Acquire Dako for $2.2 Billion
The largest acquisition in Agilent’s history is the next step in their growing role in clinical diagnostics.
Friday, May 18, 2012
Agilent Appoints Molecular Genomics as its First Certified Service Provider for Microarrays in Singapore
Molecular Genomics offers microarray services using the Agilent CGH/SNP microarrays, gene expression, and microRNA products.
Monday, July 25, 2011
Agilent Appoints BGI First Certified Service Provider in China for Target Enrichment System for Next-Gen Sequencing
Certified for all SureSelect XT target enrichment protocols including human all-exon, SureSelect indexing, DNA capture, RNA capture, kinome RNA and custom kits.
Sunday, April 17, 2011
Scientific News
Cancer Genetics: Key to Diagnosis, Therapy
When applied judiciously, cancer genetics directs caregivers to the right drug at the right time, while sparing patients of unnecessary or harmful treatments.
Scientists Identify Unique Genomic Features in Testicular Cancer
The findings may shed light on factors in other cancers that influence their sensitivity to chemotherapy.
Smart Patch Releases Blood Thinners When Needed
Researchers have developed a smart patch that activelly monitors a patient's blood and releases blood thinning drugs when necessary.
First-Ever Capsule to Treat Hemophilia
In the near future, hemophiliacs could be able to treat their disease by simply swallowing a capsule.
Enhancing CRISPR to Explore Further
Researchers have developed sOPTiKO, a more efficient and controllable CRISPR genome editing platform.
New Compound to Reduce Tumor Growth
Researchers at Stanford found that a new cell surface receptor they created is effective at inhibiting cancer growth in mice.
Long-Lasting Pill to Fight Malaria
An ultra-long acting pill has been developed to offer a new hope in eliminating malaria.
History of Cells Told Through MEMOIR
MEMOIR technique developed by CalTech researchers enables the life history of cells to be read.
Synthetic Protein Captures DNA Events Leading to Cancer
A team of scientists have developed new technology allowing them to identify molecular intermediates that can drive genetic change.
Precision Medicine for Rheumatoid Arthritis
Researchers identify gene mechanism that increases rheumatoid arthritis risk in susceptable individuals.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!